Larimar plans rolling BLA for nomlabofusp in June 2026; Q1 net loss $29.6M

Larimar Therapeutics, Inc.

Net loss Q1 2026 $29.6M ($0.31/sh) vs Q1 2025 $29.3M ($0.46/sh). Cash $200.4M.
Intends to initiate rolling BLA seeking accelerated approval June 2026; CMC module H2 2026.
Topline open-label study data expected Q2 2026; Phase 3 first patient dose mid-2026.
Breakthrough Therapy Designation granted Feb 2026. Skin frataxin as surrogate endpoint supported by published data.
Feb 2026 $115M public offering extended cash runway into Q2 2027.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.